Trevena (NASDAQ: TRVN) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Trevena to similar businesses based on the strength of its profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.
Risk & Volatility
Trevena has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Comparatively, Trevena’s peers have a beta of 2.33, meaning that their average stock price is 133% more volatile than the S&P 500.
This table compares Trevena and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Trevena and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trevena||$3.75 million||-$102.99 million||-1.06|
|Trevena Competitors||$290.27 million||$35.99 million||58.88|
Trevena’s peers have higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Trevena and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trevena currently has a consensus price target of $8.65, suggesting a potential upside of 394.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.88%. Given Trevena’s stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than its peers.
Insider and Institutional Ownership
56.1% of Trevena shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.6% of Trevena shares are held by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Trevena peers beat Trevena on 7 of the 13 factors compared.
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.